François Thomas
Director/Board Member at AELIS FARMA
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Pier Vincenzo Piazza | M | 63 | 11 years | |
Stéphane Degove | M | - |
GamaMabs Pharma SA
GamaMabs Pharma SA Medical/Nursing ServicesHealth Services GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France. | - |
Thierry Hercend | M | - |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France.
GamaMabs Pharma SA
GamaMabs Pharma SA Medical/Nursing ServicesHealth Services GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France. | - |
Sidarth Radjou | M | - |
Biomodex SAS
Biomodex SAS Commercial Printing/FormsCommercial Services Biomodex SAS develops 3D printed surgical simulators for medical education and patient-specific preoperative planning. It offers simulators for surgical procedures such as bone drilling, soft tissue suturing, medical device implantation, and sizing. The company was founded by Thomas Marchand and Sidarth Radjou on January 22, 2015 and is headquartered in Paris, France. | 9 years |
Jean-Jacques Garaud | M | 69 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | 11 years |
Michel Berg | M | - |
Axilum Robotics SAS
Axilum Robotics SAS Miscellaneous Commercial ServicesCommercial Services Axilum Robotics SAS develops and commercializes robotic solutions designed to assist medical professionals in the implementation of technical gestures. Its first project is a robot to assist psychiatrists and neurologists for Transcranial Magnetic Stimulation (TMS). The firm's project TMS is a painless, non invasive medical technique that applies high intensity magnetic impulses to cortex areas by placing a coil on the surface of the head. The company was founded by Bernard Bayle, Michel Berg, Michel de Mathelin, Romuald Ginhoux, Benjamin Maurin and Pierre Renaud in April 2011 and is headquartered in Strasbourg, France. | 13 years |
Edouard Brunet | M | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | 5 years |
Francine Behar-Cohen | M | - |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | 16 years |
Benjamin Maurin | M | - |
Axilum Robotics SAS
Axilum Robotics SAS Miscellaneous Commercial ServicesCommercial Services Axilum Robotics SAS develops and commercializes robotic solutions designed to assist medical professionals in the implementation of technical gestures. Its first project is a robot to assist psychiatrists and neurologists for Transcranial Magnetic Stimulation (TMS). The firm's project TMS is a painless, non invasive medical technique that applies high intensity magnetic impulses to cortex areas by placing a coil on the surface of the head. The company was founded by Bernard Bayle, Michel Berg, Michel de Mathelin, Romuald Ginhoux, Benjamin Maurin and Pierre Renaud in April 2011 and is headquartered in Strasbourg, France. | 13 years |
Jean-François Prost | M | 71 |
GamaMabs Pharma SA
GamaMabs Pharma SA Medical/Nursing ServicesHealth Services GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France. | - |
Patricia Zilliox | M | - |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | 8 years |
Marc Derive | M | - |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | 11 years |
Romuald Ginhoux | M | - |
Axilum Robotics SAS
Axilum Robotics SAS Miscellaneous Commercial ServicesCommercial Services Axilum Robotics SAS develops and commercializes robotic solutions designed to assist medical professionals in the implementation of technical gestures. Its first project is a robot to assist psychiatrists and neurologists for Transcranial Magnetic Stimulation (TMS). The firm's project TMS is a painless, non invasive medical technique that applies high intensity magnetic impulses to cortex areas by placing a coil on the surface of the head. The company was founded by Bernard Bayle, Michel Berg, Michel de Mathelin, Romuald Ginhoux, Benjamin Maurin and Pierre Renaud in April 2011 and is headquartered in Strasbourg, France. | 13 years |
Alexandre Carrot | M | - |
Sofimac Régions SAS
Sofimac Régions SAS Investment ManagersFinance Sofimac Régions SAS is a Private Equity/Venture Capital firm, a subsidiary of Sofimac Investment Managers SAS founded in 1978. Sofimac Régions is headquartered in Clermont-Ferrand. | 6 years |
Brice Delome | M | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | 11 years |
Augustin Palle | M | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | 5 years |
David Shu | M | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | 11 years |
Ziad Rouag | M | - |
Biomodex SAS
Biomodex SAS Commercial Printing/FormsCommercial Services Biomodex SAS develops 3D printed surgical simulators for medical education and patient-specific preoperative planning. It offers simulators for surgical procedures such as bone drilling, soft tissue suturing, medical device implantation, and sizing. The company was founded by Thomas Marchand and Sidarth Radjou on January 22, 2015 and is headquartered in Paris, France. | 5 years |
Solenn Lenfant | F | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | 4 years |
Vianney Barre | M | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | 5 years |
Alejandra Gil Duran | F | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | 5 years |
Karen Linehan | F | 65 | 2 years | |
Martine George | M | 76 |
GamaMabs Pharma SA
GamaMabs Pharma SA Medical/Nursing ServicesHealth Services GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France. | - |
Pascal Neuville | M | 60 |
Axilum Robotics SAS
Axilum Robotics SAS Miscellaneous Commercial ServicesCommercial Services Axilum Robotics SAS develops and commercializes robotic solutions designed to assist medical professionals in the implementation of technical gestures. Its first project is a robot to assist psychiatrists and neurologists for Transcranial Magnetic Stimulation (TMS). The firm's project TMS is a painless, non invasive medical technique that applies high intensity magnetic impulses to cortex areas by placing a coil on the surface of the head. The company was founded by Bernard Bayle, Michel Berg, Michel de Mathelin, Romuald Ginhoux, Benjamin Maurin and Pierre Renaud in April 2011 and is headquartered in Strasbourg, France. | - |
Jérôme Chevalier | M | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | 12 years |
Irina Staatz-Granzer | M | 64 | 2 years | |
Karina Hansen | M | 51 | 2 years | |
Gerald D. Cagle | M | 79 |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | 6 years |
Timothee Mas | M | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | - |
Akissi Tiemele Yao | F | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | 10 years |
Vianney Airaud | M | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | 3 years |
Helle Mengel | M | - | - | |
Léa Floquet | F | - | 3 years | |
Guillaume Escolier | M | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | 6 years |
Marie Line Lefevre | F | - | - | |
Romain Stokes | M | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | 3 years |
Jean-Edwin Rhea | M | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | 4 years |
Julien Levy | M | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | - |
Stéphanie Monlezun | M | - | - | |
Brahim Guetarni | M | 47 | 3 years | |
Johannes Zanzinger | M | - |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | - |
Steffen Brand | M | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | 3 years |
Amraj Bhullar | M | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | 5 years |
Amine Baji | M | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | 7 years |
Adrien Galand | M | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | - |
Luke Beshar | M | 65 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | - |
Karl Schweitzer | M | - |
Biomodex SAS
Biomodex SAS Commercial Printing/FormsCommercial Services Biomodex SAS develops 3D printed surgical simulators for medical education and patient-specific preoperative planning. It offers simulators for surgical procedures such as bone drilling, soft tissue suturing, medical device implantation, and sizing. The company was founded by Thomas Marchand and Sidarth Radjou on January 22, 2015 and is headquartered in Paris, France. | 4 years |
Jean de Gunzburg | M | - |
Cardiawave SA
Cardiawave SA Medical SpecialtiesHealth Technology Cardiawave SA develops non-invasive medical device to treat a heart condition called aortic stenosis. The company was founded by Emmanuel Messas, Benjamin Bertrand, Mickaël Tanter, Mathieu Pernot and Mathias Fink on October 21, 2014 and is headquartered in Paris, France. | - |
Dominik Escher | M | - |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | 4 years |
Arthur A. Seeligson | M | 65 |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | - |
Edmond Alphandéry | M | 80 |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | - |
Anders Gersel Pedersen | M | 73 | 4 years | |
Bernard Saint-André | M | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | - |
Thomas Möller | M | 54 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | - |
Catherine Boule | F | - |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | - |
Jacques Lewiner | M | - |
Axilum Robotics SAS
Axilum Robotics SAS Miscellaneous Commercial ServicesCommercial Services Axilum Robotics SAS develops and commercializes robotic solutions designed to assist medical professionals in the implementation of technical gestures. Its first project is a robot to assist psychiatrists and neurologists for Transcranial Magnetic Stimulation (TMS). The firm's project TMS is a painless, non invasive medical technique that applies high intensity magnetic impulses to cortex areas by placing a coil on the surface of the head. The company was founded by Bernard Bayle, Michel Berg, Michel de Mathelin, Romuald Ginhoux, Benjamin Maurin and Pierre Renaud in April 2011 and is headquartered in Strasbourg, France. | - |
Sven Zimmermann | M | 53 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | 3 years |
Graziano Seghezzi | M | 55 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | - |
Gilles Nobécourt | M | 67 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | - |
Pascal Daloz | M | 54 |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | - |
Armelle Graciet | M | - |
Cardiawave SA
Cardiawave SA Medical SpecialtiesHealth Technology Cardiawave SA develops non-invasive medical device to treat a heart condition called aortic stenosis. The company was founded by Emmanuel Messas, Benjamin Bertrand, Mickaël Tanter, Mathieu Pernot and Mathias Fink on October 21, 2014 and is headquartered in Paris, France. | - |
Ena Prossner | M | 58 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | 4 years |
Colette Lewiner | M | 77 |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | - |
Henri de Perignon | M | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | 23 years |
Chahra Khaoua Epouse Louafi | F | 53 |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | - |
Jean-Luc Boulnois | M | - |
Biomodex SAS
Biomodex SAS Commercial Printing/FormsCommercial Services Biomodex SAS develops 3D printed surgical simulators for medical education and patient-specific preoperative planning. It offers simulators for surgical procedures such as bone drilling, soft tissue suturing, medical device implantation, and sizing. The company was founded by Thomas Marchand and Sidarth Radjou on January 22, 2015 and is headquartered in Paris, France. | - |
Raphaël Durand | M | 56 |
Axilum Robotics SAS
Axilum Robotics SAS Miscellaneous Commercial ServicesCommercial Services Axilum Robotics SAS develops and commercializes robotic solutions designed to assist medical professionals in the implementation of technical gestures. Its first project is a robot to assist psychiatrists and neurologists for Transcranial Magnetic Stimulation (TMS). The firm's project TMS is a painless, non invasive medical technique that applies high intensity magnetic impulses to cortex areas by placing a coil on the surface of the head. The company was founded by Bernard Bayle, Michel Berg, Michel de Mathelin, Romuald Ginhoux, Benjamin Maurin and Pierre Renaud in April 2011 and is headquartered in Strasbourg, France. | - |
Neena Kadaba | M | - |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | 4 years |
Nancy L. Rose | M | 64 |
Massachusetts Institute of Technology
| 29 years |
Edward Colby | M | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | - |
Jason Robert Dinges | M | 48 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | - |
Ohad Hammer | M | - |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | - |
Nausicaa Lemaire | F | - |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ioannis Kymissis | M | - |
Massachusetts Institute of Technology
| 9 years |
Nick Glover | M | 55 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 3 years |
Benjamin van Roy | M | - |
Massachusetts Institute of Technology
| 9 years |
Michael Zhang | M | - |
Massachusetts Institute of Technology
| 11 years |
William Feehery | M | 54 |
Massachusetts Institute of Technology
| 5 years |
Sami Shalabi | M | - |
Massachusetts Institute of Technology
| 5 years |
Feng Li | M | 56 |
Massachusetts Institute of Technology
| 4 years |
Ilya Lisansky | M | - |
Massachusetts Institute of Technology
| 4 years |
Kathy Chiu | F | - |
Massachusetts Institute of Technology
| 5 years |
Georgios Alexopoulos | M | - |
Massachusetts Institute of Technology
| 5 years |
Rob Burn | M | - |
Massachusetts Institute of Technology
| 5 years |
Eric R. Cosman | M | - |
Massachusetts Institute of Technology
| 5 years |
Sung-Hwan Shin | M | 61 |
Massachusetts Institute of Technology
| 7 years |
Simo Kamppari | M | - |
Massachusetts Institute of Technology
| 4 years |
Craig Griffin | M | - |
Massachusetts Institute of Technology
| 5 years |
Philip Frost | M | 84 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 5 years |
Paul Carey Konigsberg | M | - |
Massachusetts Institute of Technology
| 4 years |
Matthias B. Jaffé | M | 50 |
Massachusetts Institute of Technology
| 3 years |
Katie Hall | M | - |
Massachusetts Institute of Technology
| 9 years |
Maria Staton | F | 54 |
Massachusetts Institute of Technology
| 2 years |
Gideon Stein | M | - |
Massachusetts Institute of Technology
| 5 years |
Mohsin Ansari | M | - |
Massachusetts Institute of Technology
| 2 years |
Morten Westye Høegh | M | 51 |
Massachusetts Institute of Technology
| 4 years |
Eve Phillips | F | - |
Massachusetts Institute of Technology
| 5 years |
Evren Ünver | M | - |
Massachusetts Institute of Technology
| 5 years |
Adnan Lawai | M | - |
Massachusetts Institute of Technology
| 7 years |
Ming-Hokng Maa | M | 48 |
Massachusetts Institute of Technology
| 5 years |
Statistics
Country | Connections | % of total |
---|---|---|
France | 72 | 72.00% |
United States | 26 | 26.00% |
United Kingdom | 2 | 2.00% |
Belgium | 0 | -.--% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- François Thomas
- Personal Network